Cerulean Pharma Inc. CEO Christopher Guiffre told BioWorld Today his firm’s potential $1.1 billion agreement with Novartis AG could be “the deal that put us back on the map after the setback that we had in August” in phase II with lead nanoparticle-drug conjugate (NDC) CRLX101 for advanced renal cell carcinoma (RCC).